{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:45:22Z","timestamp":1778863522055,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-024-00668-7","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T06:02:07Z","timestamp":1729922527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Virologically suppressed switch to Dolutegravir\/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States"],"prefix":"10.1186","volume":"21","author":[{"given":"Gerald","family":"Pierone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassidy E.","family":"Henegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Wohlfeiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"14","key":"668_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s40265-013-0121-4","volume":"73","author":"AD Ballantyne","year":"2013","unstructured":"Ballantyne AD, Perry CM. Dolutegravir: first global approval. Drugs. 2013;73(14):1627\u201337.","journal-title":"Drugs"},{"key":"668_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-018-0896-4","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A. Bictegravir: first global approval. Drugs. 2018;78:601\u20136.","journal-title":"Drugs"},{"issue":"4","key":"668_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/hiv.12421","volume":"18","author":"S Teeraananchai","year":"2017","unstructured":"Teeraananchai S, Kerr S, Amin J, Ruxrungtham K, Law M. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256\u201366.","journal-title":"HIV Med"},{"issue":"5","key":"668_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/COH.0000000000000298","volume":"11","author":"G Wandeler","year":"2016","unstructured":"Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492\u2013500.","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"668_CR5","doi-asserted-by":"publisher","first-page":"e25449","DOI":"10.1002\/jia2.25449","volume":"23","author":"D Back","year":"2020","unstructured":"Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23(2):e25449.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"668_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/apc.2015.0199","volume":"30","author":"HB Krentz","year":"2016","unstructured":"Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS. 2016;30(1):11\u20137.","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"668_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/microorganisms10020433","volume":"10","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2022","unstructured":"P\u00e9rez-Gonz\u00e1lez A, Su\u00e1rez-Garc\u00eda I, Ocampo A, Poveda E. Two-drug regimens for HIV - Current evidence, Research Gaps and Future challenges. Microorganisms. 2022;10(2):433.","journal-title":"Microorganisms"},{"issue":"2","key":"668_CR8","doi-asserted-by":"publisher","first-page":"e0148231","DOI":"10.1371\/journal.pone.0148231","volume":"11","author":"JG Baril","year":"2016","unstructured":"Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-Naive or ARV-Experienced, virologically suppressed patients. PLoS ONE. 2016;11(2):e0148231.","journal-title":"PLoS ONE"},{"key":"668_CR9","doi-asserted-by":"crossref","unstructured":"Pierone G, Fusco JS, Vannappagari V, Brunet L, Weber RP, Aboud M et al. Dolutegravir\/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting. Antivir Ther. 2022;27(1).","DOI":"10.1177\/13596535211073235"},{"key":"668_CR10","unstructured":"U.S, Food, Drug Administration. &. FDA approved changes to the DOVATO (dolutegravir\/lamivudine) product labeling 2020 [updated 08\/07\/2020. https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approved-changes-dovato-dolutegravirlamivudine-product-labeling"},{"key":"668_CR11","doi-asserted-by":"crossref","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla J et al. Efficacy and safety of switching to Dolutegravir\/Lamivudine fixed-dose two-drug Regimen Versus Continuing a Tenofovir Alafenamide-based three- or four-drug regimen for maintenance of Virologic Suppression in adults with HIV-1: phase 3, Randomized, non-inferiority TANGO study. Clin Infect Dis. 2020.","DOI":"10.1093\/cid\/ciz1243"},{"issue":"3","key":"668_CR12","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/jac\/dkaa479","volume":"76","author":"D Rial-Crestelo","year":"2020","unstructured":"Rial-Crestelo D, de Miguel R, Montejano R, Dominguez-Dominguez L, Aranguren-Rivas P, Esteban-Cantos A, et al. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. J Antimicrob Chemother. 2020;76(3):738\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"668_CR13","doi-asserted-by":"crossref","unstructured":"Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN et al. No significant changes to residual Viremia after switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019;6(3).","DOI":"10.1093\/ofid\/ofz056"},{"key":"668_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jgar.2019.08.010","volume":"20","author":"V Cento","year":"2020","unstructured":"Cento V, Perno CF. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-na\u00efve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety. J Glob Antimicrob Resist. 2020;20:228\u201337.","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"668_CR15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2022","unstructured":"Llibre JM, Brites C, Cheng C-Y, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and safety of switching to the 2-Drug Regimen Dolutegravir\/Lamivudine Versus Continuing a 3- or 4-Drug regimen for maintaining Virologic suppression in adults living with Human Immunodeficiency Virus 1 (HIV-1): Week 48 results from the phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2022;76(4):720\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"668_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/hiv.13050","volume":"22","author":"YS Punekar","year":"2021","unstructured":"Punekar YS, Parks D, Joshi M, Kaur S, Evitt L, Chounta V, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV Med. 2021;22(6):423\u201333.","journal-title":"HIV Med"},{"issue":"11","key":"668_CR17","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3390\/v14112558","volume":"14","author":"KH Lee","year":"2022","unstructured":"Lee KH, Kim J, Lee JA, Kim CH, Ahn JY, Jeong SJ, et al. Real-world effectiveness, tolerability, and Safety of Dolutegravir\/Lamivudine in Korea. Viruses. 2022;14(11):2558.","journal-title":"Viruses"},{"issue":"8","key":"668_CR18","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.3390\/v15081740","volume":"15","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Sasset L, Gardin S, Leoni D, Trunfio M, Scaglione V, et al. Real-life experience on Dolutegravir and Lamivudine as initial or switch therapy in a Silver Population living with HIV. Viruses. 2023;15(8):1740.","journal-title":"Viruses"},{"issue":"8","key":"668_CR19","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/jac\/dkad189","volume":"78","author":"A Mart\u00ednez-Serra","year":"2023","unstructured":"Mart\u00ednez-Serra A, De Lazzari E, Berrocal L, Foncillas A, De La Mora L, Inciarte A, et al. Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study. J Antimicrob Chemother. 2023;78(8):1955\u201362.","journal-title":"J Antimicrob Chemother"},{"key":"668_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jgar.2022.11.010","volume":"32","author":"R Gagliardini","year":"2023","unstructured":"Gagliardini R, Lorenzini P, Cozzi-Lepri A, Tavelli A, Borghi V, Galli L, et al. Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures. J Global Antimicrob Resist. 2023;32:158\u201363.","journal-title":"J Global Antimicrob Resist"},{"key":"668_CR21","doi-asserted-by":"crossref","unstructured":"Ward D, Scheibel SF, Ramgopal M, Riedel DJ, Garris C, Oglesby A, et al. editors. 2485. Real-world experience with Dolutegravir Plus Rilpivirine two-drug Regimen. Open Forum Infectious Diseases; 2019.","DOI":"10.1093\/ofid\/ofz360.2163"},{"key":"668_CR22","unstructured":"Centers for Disease Control and Prevention, Surveillance Report HIV. 2021; vol. 34 2023 [updated 23 May 2023. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance\/vol-34\/index.html"},{"key":"668_CR23","doi-asserted-by":"crossref","unstructured":"Meyer D, Slone SE, Ogungbe O, Duroseau B, Farley JE. Impact of the COVID-19 pandemic on HIV Healthcare Service Engagement, Treatment Adherence, and viral suppression in the United States: a systematic literature review. AIDS Behav. 2022.","DOI":"10.1007\/s10461-022-03771-w"},{"issue":"2","key":"668_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11904-021-00543-4","volume":"18","author":"JZ Budak","year":"2021","unstructured":"Budak JZ, Scott JD, Dhanireddy S, Wood BR. The impact of COVID-19 on HIV Care provided via Telemedicine\u2014Past, Present, and Future. Curr HIV\/AIDS Rep. 2021;18(2):98\u2013104.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"668_CR25","doi-asserted-by":"crossref","unstructured":"Pierone GJ, Fusco JS, Brunet L, Henegar C, van Wyk J, Sarkar S, et al. editors. The Impact of the COVID-19 Pandemic on Clinical Follow-up, Monitoring and Regimen Discontinuation for People Living with HIV in the US. IDWeek; 2021; Virtual Event.","DOI":"10.1093\/ofid\/ofab466.1081"},{"issue":"5","key":"668_CR26","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/jac\/dkz009","volume":"74","author":"G Baldin","year":"2019","unstructured":"Baldin G, Ciccullo A, Borghetti A, Di Giambenedetto S. Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019;74(5):1461\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"668_CR27","doi-asserted-by":"publisher","first-page":"105893","DOI":"10.1016\/j.ijantimicag.2020.105893","volume":"55","author":"N Galizzi","year":"2020","unstructured":"Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell\u2019Acqua R, et al. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. Int J Antimicrob Agents. 2020;55(3):105893.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"668_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12879-018-3666-8","volume":"19","author":"A Borghetti","year":"2019","unstructured":"Borghetti A, Lombardi F, Gagliardini R, Baldin G, Ciccullo A, Moschese D, et al. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis. 2019;19(1):59.","journal-title":"BMC Infect Dis"},{"key":"668_CR29","doi-asserted-by":"crossref","unstructured":"Ciccullo A, Borghi V, Giacomelli A, Cossu MV, Sterrantino G, Latini A et al. Five years with Dolutegravir Plus Lamivudine as a switch strategy: much more than a positive finding. JAIDS J Acquir Immune Defic Syndr. 2021;88(3).","DOI":"10.1097\/QAI.0000000000002787"},{"key":"668_CR30","doi-asserted-by":"crossref","unstructured":"Nasreddine R, Yombi JC, Darcis G, Florence E, Allard SD, De Scheerder MA et al. Efficacy, durability, and tolerability of dolutegravir\/lamivudine and dolutegravir\/rilpivirine for the treatment of HIV in a real-world setting in Belgium. HIV Med. 2022;n\/a(n\/a).","DOI":"10.1111\/hiv.13373"},{"issue":"6","key":"668_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","volume":"54","author":"G Baldin","year":"2019","unstructured":"Baldin G, Ciccullo A, Rusconi S, Capetti A, Sterrantino G, Colafigli M, et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54(6):728\u201334.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"668_CR32","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","volume":"10","author":"R Patel","year":"2021","unstructured":"Patel R, Evitt L, Mariolis I, Di Giambenedetto S, d\u2019Arminio Monforte A, Casado J, et al. HIV Treatment with the two-drug Regimen Dolutegravir Plus Lamivudine in Real-world clinical practice: a systematic literature review. Infect Dis Ther. 2021;10(4):2051\u201370.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"668_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/10600280211034176","volume":"56","author":"I Mendoza","year":"2022","unstructured":"Mendoza I, L\u00e1zaro A, Torralba M, Effectiveness. Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a real-life cohort of HIV-Infected adults. Ann Pharmacother. 2022;56(4):412\u201321.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"668_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1089\/apc.2021.0011","volume":"35","author":"G Schuettfort","year":"2021","unstructured":"Schuettfort G, Cabello A, Cotter AG, Leuw PDE, G\u00f3rgolas M, Hamzah L, et al. Reasons for choice of antiretroviral regimens in HIV patients presenting late for initial treatment in Europe. AIDS Patient Care STDs. 2021;35(4):110\u20135.","journal-title":"AIDS Patient Care STDs"},{"issue":"5","key":"668_CR35","doi-asserted-by":"publisher","first-page":"e0232473","DOI":"10.1371\/journal.pone.0232473","volume":"15","author":"W Davis","year":"2020","unstructured":"Davis W, Mantsios A, Karver T, Murray M, Punekar Y, Ward D, et al. It made me more confident that I have it under control: patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. PLoS ONE. 2020;15(5):e0232473.","journal-title":"PLoS ONE"},{"key":"668_CR36","unstructured":"Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas. 2020. HIV Surveillance Report [Internet]. 2022; 33. http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html"},{"issue":"32","key":"668_CR37","doi-asserted-by":"publisher","first-page":"e16813","DOI":"10.1097\/MD.0000000000016813","volume":"98","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Cort\u00e9s LL, Guti\u00e9rrez A, Santos J, Omar M, G\u00e1lvez C, et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine. 2019;98(32):e16813.","journal-title":"Medicine"},{"key":"668_CR38","doi-asserted-by":"crossref","unstructured":"Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S et al. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018.","DOI":"10.1111\/hiv.12611"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-024-00668-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T18:04:14Z","timestamp":1729965854000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-024-00668-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1186\/s12981-024-00668-7","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board (IRB) approval covering patient data contained in the OPERA database was received from Advarra IRB; a waiver of informed consent and authorization for the use of protected health information for patient data was granted (Pro00023648). The study was conducted in accordance with HIPAA and HITECH requirements, which expand upon the ethical principles detailed in the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GP, MBW, and AM are members of the Epidemiology and Clinical Advisory Board for Epividian. MBW has participated in post-conference advisory boards for the Conference on Retroviruses and Opportunistic Infections and International AIDS Conference and serves as a principal investigator on ViiV Healthcare clinical trials but does not receive personal compensation for this work, which goes directly to the AIDS Healthcare Foundation. AM receives research funding from Gilead, ViiV, GSK, Abbott, Roche, and Merck. He has attended advisory boards for Gilead, ViiV, and Epividian. JSF, LB, and GPF are employed by Epividian, Inc.; Epividian has had research funded by ViiV Healthcare, Merck & Co., Janssen, Gilead Sciences, Theratechnologies, EMD Serono, and AIDS Healthcare Foundation. VV, SS, CEH, and JvW are employed by ViiV Healthcare and hold stock in GSK as part of their employment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}